Accession Number: | 0001209191-21-037189 |
Date: | 2021-05-28 |
Issuer: | VYNE THERAPEUTICS INC. (VYNE) |
Original Submission Date: |
DOMZALSKI DAVID
520 U.S. HIGHWAY 22, SUITE 204
BRIDGEWATER, NJ 08807
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-05-28 | A | 941 | a | $3.36 | 474,458 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | these shares were acquired under the issuer's employee share purchase plan ("espp") for the espp purchase period beginning on december 1, 2020 and ending on may 31, 2021 in transactions that were exempt under both rule 16b-3(d) and rule 16b-3(c). in accordance with the terms of the espp, these shares were purchased at a price equal to 85% of the fair market value closing price of the issuer's ordinary shares on may 28, 2021 (the last trading day of the offering period). |